021-51111890
购物车（）
sales@molnova.cn
ML188
CAS No. 1417700-13-0
ML188 ( —— )
产品货号. M21931 CAS No. 1417700-13-0
ML188 is a selective noncovalent SARS-CoV 3CLpro inhibitor(IC50 : 1.5 μM), with moderate MW and good enzyme and antiviral inhibitory activity.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥875 | 有现货 |
|
| 5MG | ￥1442 | 有现货 |
|
| 10MG | ￥2341 | 有现货 |
|
| 25MG | ￥4795 | 有现货 |
|
| 50MG | ￥7736 | 有现货 |
|
| 100MG | ￥10368 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称ML188
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述ML188 is a selective noncovalent SARS-CoV 3CLpro inhibitor(IC50 : 1.5 μM), with moderate MW and good enzyme and antiviral inhibitory activity.
-
产品描述ML188 is a selective noncovalent SARS-CoV 3CLpro inhibitor(IC50 : 1.5 μM), with moderate MW and good enzyme and antiviral inhibitory activity.Probe 16-(R) (ML188) is a modest molecular weight SARS-CoV 3CLpro inhibitor with demonstrated antiviral activity and a non-covalent mechanism of action.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体SARS-CoV
-
研究领域——
-
适应症——
化学信息
-
CAS Number1417700-13-0
-
分子量433.54
-
分子式C26H31N3O3
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCC(C)(C)NC(=O)[C@H](N(C(=O)c1ccco1)c1ccc(cc1)C(C)(C)C)c1cccnc1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Jacobs J , Grum-Tokars V , Zhou Y , et al. Discovery, Synthesis, And Structure-Based Optimization of a Series of?N?-(?tert?-Butyl)-2-(?N?-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease[J]. Journal of Medicinal Chemistry, 2013, 56(2):534-546.
产品手册
关联产品
-
6-Hydroxy-2-(2-pheny...
6-Hydroxy-2-(2-phenylethyl)chromone is a natural product.
-
Methyl nomilinate
Methyl nomilinate from citrus can modulate cell cycle regulators to induce cytotoxicity in human colon cancer (SW480) cells in vitro.
-
3-O-Methylviolanone
3'-O-methylviolanone has anti-inflammatory activity.
